Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.
Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.
复制标题
眼内柔红霉素用于治疗和预防外伤性增殖性玻璃体视网膜病变。
DOI：
10.1016/0002-9394(87)90286-8
复制
发表时间：
1987
影响因子：
4.2
通讯作者：
K. Heimann
中科院分区：
文献类型：
--
作者：
P. Wiedemann;Lemmen Kd;Renate Schmiedl;K. Heimann
柔红霉素已被用于治疗人类创伤后增生性玻璃体视网膜病变的晚期病例。为了减少因增生性玻璃体视网膜病变而进行的创伤手术的失败率，最近的努力已经指向了对细胞再增殖的药理学抑制。我们对15名患者在玻璃体切除术后和硅油或气体注入前进行了玻璃体内柔红霉素注射。在10分钟内输注含有7.5 μg/ml柔红霉素的溶液。14例患者获得解剖成功，1例患者再次发生牵拉性视网膜脱离。所有患者术后视力均得到改善。我们没有发现对视神经、视网膜、透镜或角膜的毒性作用。
Daunorubicin has been used in the treatment of advanced cases of human posttraumatic proliferative vitreoretinopathy. To reduce the failure rate of trauma surgery from proliferative vitreoretinopathy recent efforts have been directed toward the pharmacologic inhibition of cellular reproliferation. We administered intravitreal daunorubicin to 15 patients after vitrectomy and before silicone oil or gas injection. A solution containing 7.5 μg/ml of daunorubicin was infused over a ten-minute period. Anatomic success was obtained in 14 patients, and one patient had a renewed traction retinal detachment. Visual acuity improved in all patients postoperatively. We found no toxic effects to the optic nerve, the retina, the lens, or the cornea.
道诺霉素治疗实验性增殖性玻璃体视网膜病变。
影响因子：
4.4
作者：
Wiedemann,P;Sorgente,N;Bekhor,C;Patterson,R;Tran,T;Ryan,SJ
通讯作者：
Ryan,SJ